RedHill Biopharma Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
23
- Investments
-
4
- Share Price
-
$0.67
- (As of Tuesday Closing)
RedHill Biopharma General Information
Description
Developer of pharmaceutical drugs intended to treat gastrointestinal diseases, infectious diseases and oncology. The company develops proprietary oral small-molecule drugs with advanced clinical pipelines and United States commercial operations, enabling physicians and patients to access novel therapies for conditions with high unmet need.
Contact Information
Website
www.redhillbio.comCorporate Office
- 8311 Brier Creek Parkway
- Suite 105-161
- Raleigh, NC 27617
- United States
Corporate Office
- 8311 Brier Creek Parkway
- Suite 105-161
- Raleigh, NC 27617
- United States
RedHill Biopharma Timeline
RedHill Biopharma Stock Performance
As of 06-Oct-2020, RedHill Biopharma’s stock price is $0.67. Its current market cap is $251M with 375M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.67 | $0.67 | $0.67 - $0.72 | $251M | 375M | 30K | -$0.15 |
RedHill Biopharma Financials Summary
As of 30-Jun-2026, RedHill Biopharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| Revenue | 0 | 286 | 0 | 0 |
| EBITDA | (8,440) | (7,675) | 944 | (16,535) |
| Net Income | (2,398) | (429) | (8,268) | 23,916 |
| Total Assets | 26,274 | 25,345 | 18,043 | 23,047 |
| Total Debt | 1,075 | 1,070 | 356 | 1,173 |
RedHill Biopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
RedHill Biopharma Comparisons
Industry
Financing
Details
RedHill Biopharma Competitors (3)
One of RedHill Biopharma’s 3 competitors is Phathom Pharmaceuticals, a Formerly VC-backed company based in Florham Park, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals | Formerly VC-backed | Florham Park, NJ | ||||
| Ironwood Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Anatara Lifesciences | Formerly VC-backed | Adelaide, Australia |
RedHill Biopharma Patents
RedHill Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024405493-A1 | Combination therapy for inhibition of ebolavirus | Pending | 20-Dec-2023 | ||
| EP-4828595-A2 | Combination therapy for inhibition of ebolavirus | Pending | 20-Dec-2023 | ||
| WO-2025133697-A2 | Combination therapy for inhibition of ebolavirus | Inactive | 20-Dec-2023 | ||
| WO-2025133697-A3 | Combination therapy for inhibition of ebolavirus | Inactive | 20-Dec-2023 | ||
| US-12115150-B2 | Biomarkers of coronavirus pneumonia | Active | 15-Dec-2020 | A61K31/4409 |
RedHill Biopharma Signals
RedHill Biopharma Investments (4)
RedHill Biopharma’s most recent deal was a Corporate Asset Purchase with Ferring Pharmaceuticals (Rebyota and Clenpiq Commercialization Rights) for . The deal was made on 01-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ferring Pharmaceuticals (Rebyota and Clenpiq Commercialization Rights) | 01-Sep-2026 | Corporate Asset Purchase | Buildings and Property | ||
| RedHill Biopharma (Global Rights to Movantik) | 02-Apr-2020 | Corporate Asset Purchase | Buildings and Property | ||
| RESprotect (RP101) | 14-Aug-2014 | Corporate Asset Purchase | Buildings and Property | ||
| Heidelberg Pharma (Worldwide Rights To RHB-107, Except China, Hong Kong, Taiwan & Macau) | Corporate Asset Purchase | Buildings and Property |
RedHill Biopharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
RedHill Biopharma Exits (1)
RedHill Biopharma’s most recent exit was on 02-Apr-2020 from RedHill Biopharma (Global Rights to Movantik). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| RedHill Biopharma (Global Rights to Movantik) | 02-Apr-2020 | Completed |
|
RedHill Biopharma FAQs
-
When was RedHill Biopharma founded?
RedHill Biopharma was founded in 2009.
-
Where is RedHill Biopharma headquartered?
RedHill Biopharma is headquartered in Raleigh, NC.
-
What is the size of RedHill Biopharma?
RedHill Biopharma has 23 total employees.
-
What industry is RedHill Biopharma in?
RedHill Biopharma’s primary industry is Drug Discovery.
-
Is RedHill Biopharma a private or public company?
RedHill Biopharma is a Public company.
-
What is the current stock price of RedHill Biopharma?
As of 06-Oct-2020 the stock price of RedHill Biopharma is $0.67.
-
What is the current market cap of RedHill Biopharma?
The current market capitalization of RedHill Biopharma is $251M.
-
Who are RedHill Biopharma’s competitors?
Phathom Pharmaceuticals, Ironwood Pharmaceuticals, and Anatara Lifesciences are competitors of RedHill Biopharma.
-
What is RedHill Biopharma’s annual earnings per share (EPS)?
RedHill Biopharma’s EPS for 12 months was -$0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process